作者:Fleur M. Ferguson、Zainab M. Doctor、Scott B. Ficarro、Christopher M. Browne、Jarrod A. Marto、Jared L. Johnson、Tomer M. Yaron、Lewis C. Cantley、Nam Doo Kim、Taebo Sim、Matthew J. Berberich、Marian Kalocsay、Peter K. Sorger、Nathanael S. Gray
DOI:10.1016/j.chembiol.2019.02.015
日期:2019.6
annotation but are frequent off-targets of clinical kinase inhibitors. In this study we develop and characterize FMF-04-159-2, a tool compound that specifically targets CDK14 covalently and possesses a TAIRE kinase-biased selectivity profile. This tool compound and its reversible analog were used to characterize the cellular consequences of covalent CDK14 inhibition, including an unbiased investigation
细胞周期蛋白依赖性激酶14(CDK14)和其他TAIRE家族激酶(CDK 15-18)是缺乏功能注释,但经常成为临床激酶抑制剂的脱靶蛋白。在这项研究中,我们开发并表征了FMF-04-159-2,这是一种工具化合物,可特异性地共价靶向CDK14,并具有TAIRE激酶偏向选择性谱。该工具化合物及其可逆类似物用于表征共价CDK14抑制的细胞后果,包括使用磷酸化蛋白质组学的公正研究。为了减少混杂的脱靶活性,使用洗脱条件使卷积CDK14特异作用反卷积。这项研究表明,CDK14在细胞周期调控(尤其是有丝分裂进程)中起辅助作用,并确定了推定的CDK14底物。一起,